As outlined, the diagnoses of all different glioma entities in our cohorts from Tübingen and Cologne were based on the WHO classification 2016 (1) and the following parameter for molecular diagnostics: IDH1, ATRX, 1p/19q codeletion, and MGMT. The gene discussed is ATRX; the disease is central nervous system cancer.